大家健康(中旬版)
大傢健康(中旬版)
대가건강(중순판)
GOOD HEALTH FOR ALL
2014年
3期
22-22
,共1页
非小细胞肺癌%化疗方案%对比
非小細胞肺癌%化療方案%對比
비소세포폐암%화료방안%대비
non small cell lung cancer%chemotherapy%contrast
目的:对中晚期非小细胞肺癌采用三种不同的化疗方案进行治疗的疗效进行评价。方法:选取我院2007年至2012年期间收治的114例诊断为晚期非小细胞肺癌患者的资料进行回顾性分析。将114例患者分为 MVP组、NP组和 TP组,其中,MVP组36例患者,NP组41例患者,TP 组37例患者。 MVP组方案:经脉推注8mg/m2的 MMC ,d1;静脉点滴3mg/m2的 VDS ,d1,d8;静脉点滴80 mg/m2的 PDD ,d3;NP组方案:静脉点滴25mg/m2的 NVB ,d1;静脉点滴80mg/m2的PDD ,d3;TP组:静脉点滴175mg/m2的 PTX ,d1;静脉点滴80mg/m2的 PDD ,d3。4周为一个疗程,治疗周期为两个疗程,最后对临床疗效进行对比。结果:经过治疗,MVP组的有效率为33.2%,NP组的有效率为34.1%,TP 组的有效率为40.5%。三组患者的中位生存期分别为8.3个月、7.2个月、9.2个月;1年生存率分别为 MVP组30.5%、NP组34.1%、TP组37.8%。存在的不良反应主要为:MVP组为呕吐、恶心、骨髓抑制;NP组为呕吐、恶心、骨髓抑制及静脉炎;TP组为呕吐、恶心、骨髓抑制、脱发及肌肉关节疼痛。结论:三组化疗方案对中晚期非小细胞肺癌的治疗有效率、生存率等方面存在相似性。
目的:對中晚期非小細胞肺癌採用三種不同的化療方案進行治療的療效進行評價。方法:選取我院2007年至2012年期間收治的114例診斷為晚期非小細胞肺癌患者的資料進行迴顧性分析。將114例患者分為 MVP組、NP組和 TP組,其中,MVP組36例患者,NP組41例患者,TP 組37例患者。 MVP組方案:經脈推註8mg/m2的 MMC ,d1;靜脈點滴3mg/m2的 VDS ,d1,d8;靜脈點滴80 mg/m2的 PDD ,d3;NP組方案:靜脈點滴25mg/m2的 NVB ,d1;靜脈點滴80mg/m2的PDD ,d3;TP組:靜脈點滴175mg/m2的 PTX ,d1;靜脈點滴80mg/m2的 PDD ,d3。4週為一箇療程,治療週期為兩箇療程,最後對臨床療效進行對比。結果:經過治療,MVP組的有效率為33.2%,NP組的有效率為34.1%,TP 組的有效率為40.5%。三組患者的中位生存期分彆為8.3箇月、7.2箇月、9.2箇月;1年生存率分彆為 MVP組30.5%、NP組34.1%、TP組37.8%。存在的不良反應主要為:MVP組為嘔吐、噁心、骨髓抑製;NP組為嘔吐、噁心、骨髓抑製及靜脈炎;TP組為嘔吐、噁心、骨髓抑製、脫髮及肌肉關節疼痛。結論:三組化療方案對中晚期非小細胞肺癌的治療有效率、生存率等方麵存在相似性。
목적:대중만기비소세포폐암채용삼충불동적화료방안진행치료적료효진행평개。방법:선취아원2007년지2012년기간수치적114례진단위만기비소세포폐암환자적자료진행회고성분석。장114례환자분위 MVP조、NP조화 TP조,기중,MVP조36례환자,NP조41례환자,TP 조37례환자。 MVP조방안:경맥추주8mg/m2적 MMC ,d1;정맥점적3mg/m2적 VDS ,d1,d8;정맥점적80 mg/m2적 PDD ,d3;NP조방안:정맥점적25mg/m2적 NVB ,d1;정맥점적80mg/m2적PDD ,d3;TP조:정맥점적175mg/m2적 PTX ,d1;정맥점적80mg/m2적 PDD ,d3。4주위일개료정,치료주기위량개료정,최후대림상료효진행대비。결과:경과치료,MVP조적유효솔위33.2%,NP조적유효솔위34.1%,TP 조적유효솔위40.5%。삼조환자적중위생존기분별위8.3개월、7.2개월、9.2개월;1년생존솔분별위 MVP조30.5%、NP조34.1%、TP조37.8%。존재적불량반응주요위:MVP조위구토、악심、골수억제;NP조위구토、악심、골수억제급정맥염;TP조위구토、악심、골수억제、탈발급기육관절동통。결론:삼조화료방안대중만기비소세포폐암적치료유효솔、생존솔등방면존재상사성。
Objective :for advanced non small cell lung cancer by three different chemotherapy regimens for treatment efficacy evaluation .Methods:the data of 114 cases of diagnosis in our hospital from 2007 to 2012 were selected from the patients with advanced non -small cell lung cancer were ret-rospectively analyzed .114 patients were divided into MVP group ,NP group and TP group ,among them ,36 patients in the MVP group ,41 patients in the NP group ,37 patients in group TP .Group MVP :Meridian injection 8mg/m2 MMC ,IV drip D1 ;3mg/m2 VDS ,D1 ,D8 ;intravenous drip of 80 mg/m2 PDD ,D3 ;group NP :intravenous drip of 25mg/m2 NVB ,D1 ;intravenous drip of 80mg/m2 PDD ,D3 ;group TP :intravenous infusion of 175mg/m2 PTX ,D1 ;vein with 80mg/m2 PDD ,d3 .4 weeks for a course of treatment ,the treatment cycle is two treatment course ,finally compared the clinical efficacy .Results :after treatment ,MVP group businesslike for 33 .2% ,rate in group NP was 34 .1% ,group TP is 40 .5% effective .The median survival of patients in three groups were 8 .3 months ,7 .2 months ,9 .2 months ;1 year survival rates were 30 .5% in MVP group ,NP group 34 .1% ,TP group 37 .8% .Adverse reactions are mainly :group MVP ,nausea ,vomiting ,bone marrow suppression ;group NP ,nausea ,vomiting , bone marrow suppression and phlebitis ;group TP ,bone marrow suppression ,nausea ,vomiting ,hair loss and pain in the muscles and joints .Conclu-sion:there is similarity between treatment group three chemotherapy regimens for advanced non small cell lung cancer rate ,survival rate .